ArticleLeukemia & lymphoma2020

Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.

Douglas Tremblay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.